EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer

Merel J M van Velzen, Marieke Pape, Mirjam A G Sprangers, Jessy Joy van Kleef, Bianca Mostert, Laurens V Beerepoot, Marije Slingerland, Elske C Gootjes, Ronald Hoekstra, Lonneke V van de Poll-Franse, Nadia Haj Mohammad, Hanneke W M van Laarhoven

Journal of the National Comprehensive Cancer Network · 2024

DOI: 10.6004/jnccn.2024.7014 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024. Verfasst von Merel J M van Velzen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Stomach Neoplasms, Quality of Life, Peripheral Nervous System Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chemotherapy for various stages of gastroesophageal cancer (GEC) is often neurotoxic. Chemotherapy-induced peripheral neuropathy (CIPN) impairs health-related quality of life (HRQoL). This study investigates the incidence and severity of CIPN and its association with HRQoL in patients with GEC. Patients and Methods: Patients who received chemoradiotherapy or chemotherapy for GEC were identified from the Netherlands Cancer Registry. Patient-reported data (measured using the EORTC QLQ-CIPN20 and EORTC QLQ-C30) were collected through the Prospective Observational Cohort Study of Esophageal-Gastric Cancer Patients (POCOP) at baseline and at 3, 6, 9, 12, 18, and 24 months after treatment initiation. Linear mixed effects models were constructed to assess CIPN and the correlation between CIPN and HRQoL was analyzed using Spearman’s correlation.

Results

A total of 2,135 patients were included (chemoradiotherapy: 1,593; chemotherapy with curative intent: 295; palliative chemotherapy: 247). In all 3 treatment groups, CIPN significantly increased during treatment (adjusted mean score of CIPN at 6 months: chemoradiotherapy, 8.3 [baseline: 5.5]; chemotherapy with curative intent, 16.0 [baseline: 5.6]; palliative therapy, 25.4 [baseline: 10.7]). For chemoradiotherapy, the adjusted mean score continued to increase after treatment (24 months: 11.2). For chemotherapy with curative intent and palliative therapy, the adjusted mean score of CIPN decreased after treatment but did not return to baseline values. CIPN was negatively correlated with HRQoL in all treatment groups, although significance and strength of the correlation differed over time.

Conclusions

Because of the poor prognosis of GEC, it is essential to consider side effects of (neurotoxic) treatment. The high prevalence and association with HRQoL indicate the need for early recognition of CIPN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsStomach NeoplasmsQuality of LifePeripheral Nervous System DiseasesHumansMaleFemaleMiddle AgedAgedNetherlandsProspective StudiesAntineoplastic Combined Chemotherapy ProtocolsIncidenceAntineoplastic AgentsChemoradiotherapy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Cancer Centre Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.
  • Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
  • Department of Medical Psychology, Amsterdam Public Health, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Department of Medical Oncology, Elisabeth-Tweesteden Hospital, Tilburg, the Netherlands.

Zitieren

APA

van Velzen, M. J. M., Pape, M., Sprangers, M. A. G., van Kleef, J. J., Mostert, B., Beerepoot, L. V., Slingerland, M., Gootjes, E. C., Hoekstra, R., van de Poll-Franse, L. V., Haj Mohammad, N., & van Laarhoven, H. W. M. (2024). Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2024.7014

Vancouver

van Velzen MJM, Pape M, Sprangers MAG, van Kleef JJ, Mostert B, Beerepoot LV, et al. Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer. Journal of the National Comprehensive Cancer Network. 2024. doi:10.6004/jnccn.2024.7014

BibTeX
@article{vanVelzen2024,
  author = {van Velzen, Merel J M and Pape, Marieke and Sprangers, Mirjam A G and van Kleef, Jessy Joy and Mostert, Bianca and Beerepoot, Laurens V and Slingerland, Marije and Gootjes, Elske C and Hoekstra, Ronald and van de Poll-Franse, Lonneke V and Haj Mohammad, Nadia and van Laarhoven, Hanneke W M},
  title = {Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2024},
  doi = {10.6004/jnccn.2024.7014}
}
Kostenlos starten →